Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common type of cancers worldwide. However, current therapeutic approaches for this epidemic disease are limited, and its 5-year survival rate hasn't been improved in the past decades. Patient-derived xenograft (PDX) tumor models have become an ex...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Yang, Shuqun, Luo, Chonglin, Gu, Qingyang, Xu, Qiang, Wang, Guan, Sun, Hongye, Qian, Ziliang, Tan, Yexiong, Qin, Yuxin, Shen, Yuhong, Xu, Xiaowei, Chen, Shu-Hui, Chan, Chi-Chung, Wang, Hongyang, Mao, Mao, Fang, Douglas D.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4868698/
https://ncbi.nlm.nih.gov/pubmed/26701727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6684
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars